Status:
ENROLLING_BY_INVITATION
LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
Lead Sponsor:
Bausch Health Americas, Inc.
Conditions:
Psoriasis
Eligibility:
All Genders
18-99 years
Brief Summary
Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis
Detailed Description
Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis Who Are Candidates for Systemic...
Eligibility Criteria
Inclusion
- Diagnosis and main criteria for inclusion: a subject must have moderate to severe psoriasis diagnosed by a dermatologist
- Must be at least 18 years of age or older
- Started on or switched to a systemic psoriasis treatment within the previous 12 months. FDA-approved biologic treatments and select non-biologic treatments (eg, methotrexate, cyclosporine, or apremilast only) are permitted.
Exclusion
- The subject is unable or unwilling to provide informed consent to participate in the registry.
- The subject is participating or planning to participate in a clinical trial with a non-marketed or marketed investigational drug (i.e. Phase I-IV drug trial).
- The subject is restarting the eligible medication less than 12 months since receiving the last dose.
Key Trial Info
Start Date :
July 25 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2031
Estimated Enrollment :
3500 Patients enrolled
Trial Details
Trial ID
NCT03254667
Start Date
July 25 2017
End Date
November 1 2031
Last Update
September 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Registry
Bridgewater, New Jersey, United States, 08807